An observational study in Colorectal Neoplasms, Colorectal Cancer and Breast Cancer, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by University Health Network, Toronto · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Colorectal Neoplasms by University Health Network, Toronto — 7 open to participants now, 12 under way, none of them phase 3. Colorectal Neoplasms · University Health Network, Toronto.
Among the 25 studies in Colorectal Neoplasms by University Health Network, Toronto, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2015, is one of 10 observational ones, reaches primary completion later than 4 of the 11 other live ones, and was the 14th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →7 of the 25 studies in Colorectal Neoplasms by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18–70
University Health Network, Toronto · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8
First in 2003; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 45 across the 14 interventional studies, 220 across the 10 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
7 of the studies in Colorectal Neoplasms by University Health Network, Toronto that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02864485University Health Network, TorontoLiving Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases | 2026-11 |
| NCT05843188University Health Network, TorontoStudy of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | 2026-12-24 |
| NCT07686133University Health Network, TorontoDigital Education in Colorectal Cancer Patients | 2027-01 |
| NCT02732860University Health Network, TorontoPersonalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host | 2027-01-04 |
| NCT03364621University Health Network, TorontoComprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy | 2027-06-29 |
Add all 7 to your calendar (.ics) → With an account.
Among the 25 studies in Colorectal Neoplasms by University Health Network, Toronto, from their registry updates:
This tab as a report to print or save as PDF → With an account.
By obtaining clinical specimens from participants with triple negative breast cancer (TNBC), colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor types to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with personalized cancer treatment options
Personalized patient-derived xenografts (pPDX) are increasingly used as tools for drug development in pre-clinical settings, and have been shown to recapitulate the histology and behavior of the cancers from which they are derived. Although, they have been commonly used productively as pre-clinical disease models to study disease biology and drug response, they have not been used prospectively to inform clinical management. pPDX have been employed to inform clinical decision-making in small studies, which have shown high concordance between individual pPDX and patient responses to therapy. While encouraging, the role of this approach in breast, colorectal, ovarian, and other cancer populations and in the context of genomic drug matching strategies remains undefined. This has created an opportunity to evaluate the utility of pPDX as clinical predictors to direct the use of chemo- and targeted therapies in combination with comprehensive genomic and epigenetic analysis for patients with TNBC, CRC, HGSOC and other selected tumor types.
Patients with TNBC, CRC, HGSOC, or selected other tumour types, referred to, or being treated at Princess Margaret Cancer Centre.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient diagnosis must be categorized as either (I) OR (II) OR (III) OR (IV):
(I) confirmed Triple Negative Breast Cancer by Institutional and American Society of Clinical Oncology (ASCO)/Cancer of American Pathologists (CAP) guidelines, either:
OR
(II) Histologically-confirmed Stage IV colorectal cancer treated with ≤ 1 in the metastatic setting, either:
OR
(III) Histologically-confirmed advanced High Grade Serous Ovarian Cancer, either:
OR
(IV) Histologically confirmed solid tumor not meeting criteria for (I), (II) or (III) above, for which evaluation of therapies is of particular interest or where clinical need exists, at the discretion of the PI
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Triple negative breast cancer patients with residual invasive disease following neoadjuvant chemotherapy (n= up to 15) or with newly diagnosed metastatic disease (n=up to 30). After the screening procedures confirms patient eligibility: * Molecular Profiling will be performed on clinical sample * pPDX generation for in vivo drug testing * In vitro organoid culture generation (if sufficient fresh tissue available) * Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation.
Other: Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
Colorectal cancer patients with metastatic disease undergoing resection of liver metastases, or with lesions amenable to biopsy (n=up to 15). After the screening procedures confirms patient eligibility: * Molecular Profiling will be performed on clinical sample * pPDX generation for in vivo drug testing * In vitro organoid culture generation (if sufficient fresh tissue available) * Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation.
Other: Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
High grade serous ovarian cancer patients with recurrent disease with a life expectancy of at least 12 months (n=up to 15), or Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence (n=up to 15). After the screening procedures confirms patient eligibility: * Molecular Profiling will be performed on clinical sample * pPDX generation for in vivo drug testing * In vitro organoid culture generation (if sufficient fresh tissue available) * Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation.
Other: Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
Other selected tumor types at the discretion of the PI (n= up to 30) After the screening procedures confirms patient eligibility: * Molecular Profiling will be performed on clinical sample * pPDX generation for in vivo drug testing * In vitro organoid culture generation (if sufficient fresh tissue available) * Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation.
Other: Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.
Measure of drug sensitive pPDX to a panel of drugs as a predictor of clinical response in matched host
Sensitivity measured by tumor growth inhibition (\>80%) or objective tumor response (regression) as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
Time frame: up to 5 years
Rate of results reporting
Time frame: up to 5 years
Rate of pPDX engraftment
Time frame: up to 2 years
Comparison of actionable alterations identified in clinical and pPDX samples
Genomic alterations identified using the Ion Proton System for Next-Generation Sequencing (NGS).
Time frame: up to 5 years
Number of patients with molecular abnormalities in pPDX as identified via NGS eliciting clinical responses while receiving matched treatments.
Overall accuracy of clinical responses as assessed by RECIST criteria in patient tumor.
Time frame: up to 5 years
Correlation between pPDX and organoid drug sensitivities
Time frame: up to 5 years
The record gives a start of Dec 2015, a primary completion of Jan 2027 and a completion of Jan 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →